An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma.

Trial Profile

An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Vincristine; Zanolimumab
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2010 Results published in the British Journal of Haematology (Sep 2010: 150(5);565-573), according to a TenX Biopharma Inc media release.
    • 01 Dec 2008 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2007 Results will be presented at ASH in December 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top